Search

Your search keyword '"Tumor necrosis factor-A inhibitors"' showing total 4 results
Start Over Descriptor "Tumor necrosis factor-A inhibitors"
4 results on '"Tumor necrosis factor-A inhibitors"'

1. Single Dose of Etanercept Injection: A Game Changer in Toxic Epidermal Necrolysis: A Case Series.

Author

KANNAN, RAJKUMAR, DANIEL, SAMUEL JEYARAJ, KUMAR, PARIMALAM, and KAVIMANI, LAVANYA

Subjects
*ETANERCEPT, *SUBCUTANEOUS injections, *TOXIC epidermal necrolysis, *DRUG side effects, *INJECTIONS, *STEROID drugs
Abstract

Toxic Epidermal Necrolysis (TEN) is a rare hypersensitivity reaction to drugs, characterised by widespread erythema, full-thickness epidermal necrosis with mucosal involvement, and extensive apoptosis. It is a dermatological emergency and can be lethal if not promptly treated. The use of steroids in managing TEN is controversial since no gold standard therapy exists. However, a single dose of subcutaneous injection of Etanercept (a Tumour Necrosis Factor-alpha (TNF-a) inhibitor) at a dosage of 50 mg has shown promise in preventing mortality and reducing hospital stay. The authors present a case series of six TEN patients, out of which three received a single dose of Etanercept injection. All patients who received Etanercept showed a positive response, achieving complete re-epithelialisation with a median healing time of nine days. In conclusion, injection of Etanercept, a TNF-a inhibitor, effectively inhibits Fas-Fas ligand activation, thus preventing apoptosis and extensive necrosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

2. Characteristics predicting tuberculosis risk under tumor necrosis factor-? inhibitors: Report from a large multicenter cohort with high background prevalence

Author

Ahmet Gül, Ahmet Mesut Onat, Ayten Yazici, Sait Burak Erer, Meryem Can, Veli Cobankara, Servet Akar, Salih Pay, Levent Kilic, Bunyamin Kisacik, H. Direskeneli, Sedat Yilmaz, Fahrettin Oksel, Ayse Balkarli, Gökhan Keser, Ali Berkant Avci, Mehmet Sayarlioglu, Ihsan Ertenli, Ender Terzioglu, Ömer Nuri Pamuk, Ediz Dalkilic, Yavuz Pehlivan, Ayse Cefle, Yesim Ozguler, Süleyman Özbek, Gozde Yildirim Cetin, Gulen Hatemi, Ondokuz Mayıs Üniversitesi, Çukurova Üniversitesi, Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı., Pehlivan, Yavuz, Dalkılıç, Ediz, and AAG-8227-2021

Subjects
rheumatoid arthritis, Male, demography, age distribution, TUBERCULOSIS REACTIVATION, Tnf, ISONIAZID, tumor necrosis factor alpha inhibitor, Turkey (republic), Arthritis, Rheumatoid, 0302 clinical medicine, rituximab, adalimumab, middle aged, Prevalence, Immunology and Allergy, TUMOR NECROSIS FACTOR-A INHIBITORS, 030212 general & internal medicine, risk, psoriatic arthritis, Latent tuberculosis, adult, disease course, pathogenesis, clinical trial, cohort analysis, female, Tuberculosis reactivation isoniazid, priority journal, risk factor, tuberculosis, Rheumatoid arthritis, Antirheumatic Agents, Tumor Necrosis Factor, Skin Tests, Interferon Gamma Release Assay, Cohort, Chemoprophylaxis, biological product, Tumor necrosis factor-A inhibitors, medicine.drug, medicine.medical_specialty, isoniazid, Tuberculosis, tumor necrosis factor, sex difference, Immunology, skin test, Infections, Article, 03 medical and health sciences, Rheumatology, Latent Tuberculosis, Rheumatoid-arthritis, Internal medicine, ankylosing spondylitis, medicine, Humans, controlled study, Spondylitis, Ankylosing, human, infection risk, extrapulmonary tuberculosis, antagonists and inhibitors, 030203 arthritis & rheumatology, Ankylosing spondylitis, Biological Products, business.industry, Tumor Necrosis Factor-alpha, prediction, Adult, Antirheumatic Agents/*adverse effects/therapeutic use, Arthritis, Rheumatoid/drug therapy, Biological Products/*adverse effects/therapeutic use, Female, Latent Tuberculosis/*diagnosis, Middle Aged, Risk, Spondylitis, Ankylosing/drug therapy, Tuberculosis/*epidemiology/*etiology, Tumor Necrosis Factor-alpha/*antagonists & inhibitors, Term, medicine.disease, major clinical study, mortality, Infliximab, Surgery, clinical feature, multicenter study, Factor antagonists, antirheumatic agent, Therapy, business, infliximab, etanercept, Behcet disease
Abstract

Objective.Screening strategies for latent tuberculosis (TB) before starting tumor necrosis factor (TNF)-α inhibitors have decreased the prevalence of TB among patients who are treated with these agents. However, despite vigilant screening, TB continues to be an important problem, especially in parts of the world with a high background TB prevalence. The aim of this study was to determine the factors related to TB among a large multicenter cohort of patients who were treated with anti-TNF.Methods.Fifteen rheumatology centers participated in this study. Among the 10,434 patients who were treated with anti-TNF between September 2002 and September 2012, 73 (0.69%) had developed TB. We described the demographic features and disease characteristics of these 73 patients and compared them to 7695 patients who were treated with anti-TNF, did not develop TB, and had complete data available.Results.Among the 73 patients diagnosed with TB (39 men, 34 women, mean age 43.6 ± 13 yrs), the most frequent diagnoses were ankylosing spondylitis (n = 38) and rheumatoid arthritis (n = 25). More than half of the patients had extrapulmonary TB (39/73, 53%). Six patients died (8.2%). In the logistic regression model, types of anti-TNF drugs [infliximab (IFX), OR 3.4, 95% CI 1.88–6.10, p = 0.001] and insufficient and irregular isoniazid use (< 9 mos; OR 3.15, 95% CI 1.43–6.9, p = 0.004) were independent predictors of TB development.Conclusion.Our results suggest that TB is an important complication of anti-TNF therapies in Turkey. TB chemoprophylaxis less than 9 months and the use of IFX therapy were independent risk factors for TB development.

Published
2016

3. Factor-alpha Inhibitors: Report from a Large Multicenter Cohort with

Author

Kisacik, B, Pamuk, ON, Onat, AM, Erer, SB, Hatemi, G, Ozguler, Y, Pehlivan, Y, Kilic, L, Ertenli, I, Can, M, Direskeneli, H, Keser, G, Oksel, F, Dalkilic, E, Yilmaz, S, Pay, S, Balkarli, A, Cobankara, V, Cetin, GY, Sayarlioglu, M, Cefle, A, Yazici, A, Avci, AB, Terzioglu, E, Ozbek, S, Akar, S, and Gul, A

Subjects
TUMOR NECROSIS FACTOR-A INHIBITORS, TUBERCULOSIS REACTIVATION, ISONIAZID
Abstract

Objective. Screening strategies for latent tuberculosis (TB) before starting tumor necrosis factor (TNF)-alpha inhibitors have decreased the prevalence of TB among patients who are treated with these agents. However, despite vigilant screening, TB continues to be an important problem, especially in parts of the world with a high background TB prevalence. The aim of this study was to determine the factors related to TB among a large multicenter cohort of patients who were treated with anti-TNF. Methods. Fifteen rheumatology centers participated in this study. Among the 10,434 patients who were treated with anti-TNF between September 2002 and September 2012, 73 (0.69%) had developed TB. We described the demographic features and disease characteristics of these 73 patients and compared them to 7695 patients who were treated with anti-TNF, did not develop TB, and had complete data available. Results. Among the 73 patients diagnosed with TB (39 men, 34 women, mean age 43.6 +/- 13 yrs), the most frequent diagnoses were ankylosing spondylitis (n = 38) and rheumatoid arthritis (n = 25). More than half of the patients had extrapulmonary TB (39/73, 53%). Six patients died (8.2%). In the logistic regression model, types of anti-TNF drugs [infliximab (IFX), OR 3.4, 95% CI 1.88-6.10, p = 0.001] and insufficient and irregular isoniazid use (

Published
2016

4. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.

Author

Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, and Gul A

Subjects
Adult, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Biological Products therapeutic use, Female, Humans, Male, Middle Aged, Prevalence, Risk, Spondylitis, Ankylosing drug therapy, Antirheumatic Agents adverse effects, Biological Products adverse effects, Latent Tuberculosis diagnosis, Tuberculosis epidemiology, Tuberculosis etiology, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Objective: Screening strategies for latent tuberculosis (TB) before starting tumor necrosis factor (TNF)-α inhibitors have decreased the prevalence of TB among patients who are treated with these agents. However, despite vigilant screening, TB continues to be an important problem, especially in parts of the world with a high background TB prevalence. The aim of this study was to determine the factors related to TB among a large multicenter cohort of patients who were treated with anti-TNF., Methods: Fifteen rheumatology centers participated in this study. Among the 10,434 patients who were treated with anti-TNF between September 2002 and September 2012, 73 (0.69%) had developed TB. We described the demographic features and disease characteristics of these 73 patients and compared them to 7695 patients who were treated with anti-TNF, did not develop TB, and had complete data available., Results: Among the 73 patients diagnosed with TB (39 men, 34 women, mean age 43.6 ± 13 yrs), the most frequent diagnoses were ankylosing spondylitis (n = 38) and rheumatoid arthritis (n = 25). More than half of the patients had extrapulmonary TB (39/73, 53%). Six patients died (8.2%). In the logistic regression model, types of anti-TNF drugs [infliximab (IFX), OR 3.4, 95% CI 1.88-6.10, p = 0.001] and insufficient and irregular isoniazid use (< 9 mos; OR 3.15, 95% CI 1.43-6.9, p = 0.004) were independent predictors of TB development., Conclusion: Our results suggest that TB is an important complication of anti-TNF therapies in Turkey. TB chemoprophylaxis less than 9 months and the use of IFX therapy were independent risk factors for TB development.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results